A5033786288- Ocular Diseases and Behçet’s Syndrome
- Vasculitis and related conditions
- Otitis Media and Relapsing Polychondritis
- Systemic Sclerosis and Related Diseases
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Urticaria and Related Conditions
- Immunotherapy and Immune Responses
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Rheumatoid Arthritis Research and Therapies
- SARS-CoV-2 and COVID-19 Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Venous Thromboembolism Diagnosis and Management
- Autoimmune Bullous Skin Diseases
- Blood Coagulation and Thrombosis Mechanisms
- Eosinophilic Esophagitis
- Adolescent and Pediatric Healthcare
- Retinal and Optic Conditions
- Hepatitis C virus research
- Healthcare Systems and Reforms
- Immunodeficiency and Autoimmune Disorders
Azienda Ospedaliera Universitaria Pisana
2021-2025
University of Pisa
2021-2025
University of Siena
2024-2025
Misericordia University
2021-2023
University of Pavia
2021-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2023
Temple Street Children's University Hospital
2022
Meyer Children's Hospital
2022
University of Florence
2022
Abstract Objective Sleep disturbances significantly impact Behçet’s Syndrome (BS) patients’ quality of life. Defining the correlates BS sleep is needed to improve their management and, in turn, In this study, we explored fibromyalgia, disease activity, and glucocorticoid exposure as possible predictors circadian rhythm parameters a cohort patients. Methods Participants’ sociodemographic data were collected through survey. evaluated objectively via continuous 7-day accelerometric monitoring...
Oral and genital ulcers are the hallmark manifestation of Behçet's disease (BD), significantly impacting patients' quality life. Our study focuses on comparing effectiveness safety TNF inhibitors (TNFis) apremilast in controlling oral BD, aiming to provide evidence-based guidance for physicians selecting appropriate treatment modalities.
Behçet's syndrome (BS) represents a challenging condition, characterized by variable spectrum of disease profile and associated with significant limitation the daily activities as well potential negative impact on relationships psychological status. Considering also complexity therapeutic management BS, that often includes biological off-label treatments, participation in decision-making process BS patients is essential to ensure integration care into life patient. For this reason,...
In patients with systemic autoimmune rheumatic disorders (SARDs), vaccination SARS-CoV-2 mRNA vaccines has been proposed. The aim of this study is to evaluate the immune response elicited by vaccine, testing IgM, IgA and IgG antibodies receptor-binding domain (RBD) measuring neutralising antibodies. IgG, IgM anti-RBD were measured in 101 SARDs. Antibodies inhibiting interaction between RBD ACE2 evaluated. Antibody avidity was tested a chaotropic ELISA using urea. Twenty-one healthcare...
Evidence from randomised controlled trials on anti-tumour necrosis factor (TNF) agents in patients with Behçet's syndrome (BS) is low.
Behçet’s syndrome (BS) is a rare chronic multi-systemic inflammatory disorder that usually involves adults between third and fourth decades of life, while pediatric juvenile onset are relatively rare. BS young patients (YP) often develop full-blown disease late after onset, requiring careful diagnostic workup regular follow-up they grow up. In this regard, the purpose transitional programs to ensure continuous high-quality care YP with conditions, providing them skills necessary become...
<h3>Background</h3> Behçet's disease (BD) is a rare, and severe, multisystemic inflammatory characterized by recurrent oral aphthous ulcers, genital skin lesions, both anterior posterior uveitis; articular, vascular, gastroenteric neurological involvement may also occur. The multi-organ the wide spectrum of clinical manifestations make diagnosis BD challenging. lack medication adherence leads to poorer health outcomes for patients, which affect quality life, generate economic loss healthcare...
Background Since the COVID-19 vaccination campaign was launched all over Europe, there has been general agreement on how benefits of SARS-CoV2 vaccines outweigh risks in patients with rare connective tissue diseases (rCTDs). Yet, is still limited evidence regarding safety and efficacy such these patients, especially long-term. For this reason, framework ERN-ReCONNET, an observational long-term study (VACCINATE) designed order to explore outcome rCTDs patients. The consent form developed...